Dendritic cells vaccine(Oslo University Hospital)(Dendritic cells vaccine(Oslo University Hospital)) - 在研适应症：胶质母细胞瘤，IDH野生型，转移性前列腺癌_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤神经系统疾病其他疾病+ [1]

在研适应症

胶质母细胞瘤，IDH野生型转移性前列腺癌

非在研适应症

疲劳发热疼痛+ [2]

原研机构

Oslo universitetssykehus HF

在研机构

Oslo universitetssykehus HF

非在研机构-

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Dendritic cells vaccine(Oslo University Hospital) 相关的临床试验

NCT03548571 / Recruiting临床2/3期IIT

Open Label Randomized Phase II/III Trial of Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy (DEN-STEM)

Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma. The IMP is dendritic cells transfected with mRNA of survivin, hTERT og autologous tumor stem cells derived from tumorspheres.

开始日期2018-04-26

申办/合作机构

Oslo universitetssykehus HF

NCT01197625 / Active, not recruiting临床1/2期IIT

Trial of Vaccine Therapy in Curative Resected Prostate Cancer Patients Using Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin

In this study the investigators will include patients with high risk of PSA relapse scheduled to receive curative surgical treatment. This include patients with high Gleason score (9-10) or micrometastatic disease (tumor cells detected in specimens obtained from bone marrow). They are scheduled for regular follow-ups with PSA measurements. We have previously published that some patients with metastatic prostate cancer may respond to DC-vaccination with tumor mRNA, with a decrease in PSA. PSA response is related to immunological response. Patients receiving DC-vaccination may have a reduced risk of PSA relapse or increased time to PSA relapse. Previous experience with different DC-vaccine protocols in our hospital has resulted in only minor side-effects (grade 1-2 fever, rubor, fatigue, local swelling or pain).

开始日期2010-09-01

申办/合作机构

Oslo universitetssykehus HF

100 项与 Dendritic cells vaccine(Oslo University Hospital) 相关的临床结果

登录后查看更多信息

100 项与 Dendritic cells vaccine(Oslo University Hospital) 相关的转化医学

登录后查看更多信息

100 项与 Dendritic cells vaccine(Oslo University Hospital) 相关的专利（医药）

登录后查看更多信息

100 项与 Dendritic cells vaccine(Oslo University Hospital) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胶质母细胞瘤，IDH野生型	临床3期	挪威	Oslo universitetssykehus HF	2018-04-26
疲劳	临床2期	挪威	Oslo universitetssykehus HF	2010-09-30
发热	临床2期	挪威	Oslo universitetssykehus HF	2010-09-30
疼痛	临床2期	挪威	Oslo universitetssykehus HF	2010-09-30
涎腺多形性腺瘤	临床2期	挪威	Oslo universitetssykehus HF	2010-09-30
肿胀	临床2期	挪威	Oslo universitetssykehus HF	2010-09-30
转移性前列腺癌	临床2期	挪威	Oslo universitetssykehus HF	2010-09-01